Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®Business Wire • 02/24/26
Bausch + Lomb (BLCO) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 02/19/26
Bausch + Lomb (BLCO) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 02/18/26
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 GuidanceBusiness Wire • 02/18/26
Ahead of Bausch + Lomb (BLCO) Q4 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 02/16/26
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18Business Wire • 01/20/26
Bausch + Lomb Corporation (BLCO) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.Business Wire • 01/05/26
Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/23/25
Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past YearThe Motley Fool • 12/17/25
Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/03/25
BLCO Stock Still 16% Below IPO — Is Silver Point's $38.7 Million Bet a Turning Point?The Motley Fool • 12/03/25
Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation - Analyst/Investor Day TranscriptSeeking Alpha • 11/18/25
Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling ProgramBusiness Wire • 11/10/25
Bausch + Lomb (BLCO) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 10/29/25